Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ana Ortega Franco"'
Publikováno v:
Ciencia & Salud, Vol 8, Iss 3 (2024)
La depresión posparto comprende una complicación que ocurre en los primeros 4 meses previos al parto. El consumo de alcohol representa un problema social y de salud pública a nivel mundial. Casi 1 de cada 10 (9,8%) mujeres de la población general
Externí odkaz:
https://doaj.org/article/5480b51686294c0d80199b949799bdfd
Autor:
Erick F. Saldanha, Eleonora Nicolo, Konstantinos Venetis, Diego de Miguel-Perez, Ana Ortega-Franco, Angelo Dipasquale, Mohamed A. Gouda, Surbhi Singhal, George Adigbli, Carolina Reduzzi
Publikováno v:
The Journal of Liquid Biopsy, Vol 5, Iss , Pp 100156- (2024)
Externí odkaz:
https://doaj.org/article/5b699f2ae6014e98a8ae5423223dc0a9
Autor:
Ana Ortega-Franco, Clare Hodgson, Haseem Raja, Mathew Carter, Colin Lindsay, Sarah Hughes, Laura Cove-Smith, Paul Taylor, Yvonne Summers, Fiona Blackhall, Raffaele Califano
Publikováno v:
Targeted Oncology. 17:453-465
Pembrolizumab is licensed for the treatment of pre-treated and PD-L1 positive non-small cell lung cancer (NSCLC), but response is heterogeneous. In this context, the Lung Immune Prognostic Index (LIPI) has been proposed as tool to prognosticate outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1973db7d1d7144ae6ef854a2eb3c8893
https://doi.org/10.1007/s11523-022-00889-8
https://doi.org/10.1007/s11523-022-00889-8
Publikováno v:
Translational Lung Cancer Research. 10:3850-3854
Immune checkpoint inhibitors (ICIs) and targeted therapies have revolutionised the diagnostic and treatment paradigm of advanced non-small cell lung cancer (NSCLC). However, treatment advances in squamous cell subtype have been much slower than those
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55598e2b8a74000dcd028117cf503154
https://doi.org/10.21037/tlcr-20-715
https://doi.org/10.21037/tlcr-20-715
Publikováno v:
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 42
Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA in the bloodstream that has come from primary or metastatic cancer sites. Neoplasm-specific genetic and epigenetic abnormalities are increasingly being identified through liquid biopsy: a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d838be37d94462536ab67a8af53caaf
https://pubmed.ncbi.nlm.nih.gov/35471832
https://pubmed.ncbi.nlm.nih.gov/35471832
Autor:
Martin Reck, Christoph Jakob Ackermann, Adeel Khan, Raffaele Califano, Ana Ortega-Franco, Helen Adderley
Publikováno v:
Drugs. 80:1783-1797
The advent of PD-(L)1 and CTLA-4 immune check point inhibitors (CPIs) has dramatically changed the treatment landscape of advanced non-small-cell lung cancer (NSCLC). For up to a quarter of patients with advanced NSCLC, CPIs have the potential to ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057556318084b42f07b1ba9d60e92957
https://doi.org/10.1007/s40265-020-01409-6
https://doi.org/10.1007/s40265-020-01409-6
Autor:
Ana Ortega-Franco, Shereen Rafee
Publikováno v:
Oncology and therapy. 10(1)
The introduction of tyrosine kinase inhibitors (TKI) for the treatment of metastatic non-small cell lung cancer (NSCLC) harbouring sensitizing epidermal growth factor receptor (EGFR) gene mutations revolutionized the diagnostic and treatment algorith
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8beca3cdba03059da680cf98c892e306
https://pubmed.ncbi.nlm.nih.gov/35294773
https://pubmed.ncbi.nlm.nih.gov/35294773
Publikováno v:
Transl Lung Cancer Res
Prognosis of early stage non-small cell lung cancer (eNSCLC) is poor even when treated radically with surgery and (neo)adjuvant chemotherapy (Cht). The discovery of tyrosine kinase inhibitors (TKIs) for oncogene addicted NSCLC and immune checkpoint i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b36262bb45d98c6d913bcf7bcccd0d4
https://pubmed.ncbi.nlm.nih.gov/33489825
https://pubmed.ncbi.nlm.nih.gov/33489825
Autor:
Lucy Osborne, Ana Ortega-Franco, Clare Hodgson, Mark Pearce, Anna Moss, Colin Lindsay, Sarah Hughes, Paul Taylor, Raffaele Califano, Shereen Rafee, Fabio Gomes, Yvonne Summers, Fiona Blackhall, Laura Cove-Smith, Emma Halkyard, Jackie Fenemore
Publikováno v:
Lung Cancer. 165:S46
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e529815e53527a5492d672f0d3ca7263
https://doi.org/10.1016/s0169-5002(22)00144-1
https://doi.org/10.1016/s0169-5002(22)00144-1
Publikováno v:
ESMO Open
Small-cell lung cancer (SCLC) is an aggressive and rapidly growing disease with poor prognosis. Despite intense efforts to improve clinical outcomes, platinum/etoposide chemotherapy has remained the most effective regimen for first-line extensive dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::230320f971d1f6554b9bfc711d113b9d
https://pubmed.ncbi.nlm.nih.gov/33450659
https://pubmed.ncbi.nlm.nih.gov/33450659